Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.77 |
| ▸ | GHSR | Q92847 | 15/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20528744 | 1.00 | CYP2D6 (0.77) | CYP2D6GHSRKCNH2CYP3A4HTR2C | |
| SCHEMBL5822244 | 0.90 | GHSR (0.73) | CYP2D6GHSRKCNH2CYP3A4HTR2C | |
| SCHEMBL20528762 | 0.87 | CYP2D6 (1.00) | CYP2D6GHSRKCNH2CYP3A4 | |
| SCHEMBL20528764 | 0.87 | CYP2D6 (1.00) | CYP2D6GHSRKCNH2CYP3A4 | |
| SCHEMBL5791862 | 0.87 | CYP2D6 (0.78) | CYP2D6GHSRKCNH2CYP3A4HTR2C | |
| SCHEMBL20528740 | 0.84 | GHSR (0.60) | CYP2D6GHSRKCNH2CYP3A4HTR2C | |
| SCHEMBL20528742 | 0.84 | GHSR (0.60) | CYP2D6GHSRKCNH2CYP3A4HTR2C | |
| SCHEMBL5791441 | 0.84 | GHSR (0.76) | CYP2D6GHSRKCNH2CYP3A4HTR2C | |
| SCHEMBL21686463 | 0.83 | GHSR (0.76) | CYP2D6GHSRKCNH2CYP3A4HTR2C | |
| SCHEMBL5809122 | 0.83 | GHSR (0.73) | CYP2D6GHSRKCNH2CYP3A4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186571-B2 | Quinazolinone derivatives useful for imaging | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2021-11-30 | — | — | US | disclosed |
| US-20200031821-A1 | QUINAZOLINONE DERIVATIVES USEFUL FOR IMAGING | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2020-01-30 | — | — | US | disclosed |
| WO-2018184115-A1 | QUINAZOLINONE DERIVATIVES USEFUL FOR IMAGING | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031821-A1 | QUINAZOLINONE DERIVATIVES USEFUL FOR IMAGING | TNNI3, KLK3, BRDT | CYP2D6 409/4885GHSR 1991/4885KCNH2 143/4885 |
| US-11186571-B2 | Quinazolinone derivatives useful for imaging | TNNI3, KLK3, BRDT | CYP2D6 409/4885GHSR 1991/4885KCNH2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.